MedTrace Logo

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

NCT06244082 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-05-14

No results posted yet for this study

Summary

AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.

Conditions

Interventions

DRUG

AOC 1044

AOC 1044 will be administered via intravenous (IV) infusion

Sponsors & Collaborators

  • Avidity Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Carmen Castrillo, MD · Avidity Biosciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
27 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-22
Primary Completion
2027-04-30
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06244082 on ClinicalTrials.gov